Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

139.51USD
22 May 2019
Change (% chg)

$1.03 (+0.74%)
Prev Close
$138.48
Open
$138.00
Day's High
$140.11
Day's Low
$137.81
Volume
222,721
Avg. Vol
602,578
52-wk High
$197.00
52-wk Low
$125.84

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.32
Market Cap(Mil.): $45,731.64
Shares Outstanding(Mil.): 327.80
Dividend: 0.74
Yield (%): 2.12

Financials

  AGN.N Industry Sector
P/E (TTM): -- 30.96 35.38
EPS (TTM): -21.63 -- --
ROI: -7.40 12.01 11.72
ROE: -10.81 13.30 16.38

Allergan wins less than $50,000 in case against compounder Imprimis

A federal jury on Thursday awarded Allergan PLC less than $50,000 of the millions of dollars it sought in a false advertising lawsuit seeking to stop Imprimis Pharmaceuticals Inc from selling certain compounded drugs that bypass regulatory approval, including a cheaper alternative to Allergan's dry eye drug Restasis, according to a lawyer for Imprimis.

May 17 2019

Allergan CEO says company is urgently looking at all options to boost share price

Allergan Plc Chief Executive Brent Saunders said on Tuesday that he and the board of directors were looking with a sense of urgency at all options to revive the Botox maker's falling share price, but a lack of specifics failed to boost investor sentiment.

May 07 2019

UPDATE 3-Allergan CEO says company is urgently looking at all options to boost share price

May 7 Allergan Plc Chief Executive Brent Saunders said on Tuesday that he and the board of directors were looking with a sense of urgency at all options to revive the Botox maker's falling share price, but a lack of specifics failed to boost investor sentiment.

May 07 2019

Allergan reports bigger first-quarter loss on $2.5 bln charge

May 7 Allergan Plc posted a bigger first-quarter loss on Tuesday as it recorded a charge of about $2.5 billion related to the clinical failure of its depression treatment candidate rapastinel.

May 07 2019

Allergan CEO Saunders wins vote to keep chairman role

NEW YORK Allergan Plc shareholders have voted down a nonbinding proposal that sought an immediate split of the roles of chairman and chief executive, with 61.3 percent of shareholders backing Chairman and CEO Brent Saunders.

May 01 2019

UPDATE 3-Allergan CEO Saunders wins vote to keep chairman role

NEW YORK, May 1 Allergan Plc shareholders have voted down a nonbinding proposal that sought an immediate split of the roles of chairman and chief executive, with 61.3 percent of shareholders backing Chairman and CEO Brent Saunders.

May 01 2019

CORRECTED-UPDATE 1-Allergan CEO Saunders wins vote to keep chairman role

NEW YORK, May 1 Allergan Plc shareholders have voted down a non-binding proposal that sought an immediate split of the roles of chairman and chief executive, with 61.3 percent of shareholders backing Chairman and CEO Brent Saunders.

May 01 2019

CORRECTED-Allergan CEO Saunders wins vote to keep chairman role

NEW YORK, May 1 Allergan Plc shareholders have voted down a non-binding proposal that sought an immediate split of the roles of chairman and chief executive, with 61.3 percent of shareholders backing Chairman and CEO Brent Saunders.

May 01 2019

Allergan to prevail in vote over CEO Saunders' chairman role-sources

Allergan Plc is on course to defeat a non-binding shareholder resolution tabled by David Tepper's hedge fund Appaloosa LP that would have instructed the drugmaker's CEO Brent Saunders to immediately give up his role as chairman, people familiar with the matter said on Tuesday.

Apr 30 2019

CORRECTED-Allergan to prevail in vote over CEO Saunders' chairman role-sources

April 30 Allergan Plc is on course to defeat a non-binding shareholder resolution tabled by David Tepper's hedge fund Appaloosa LP that would have instructed the drugmaker's CEO Brent Saunders to immediately give up his role as chairman, people familiar with the matter said on Tuesday.

Apr 30 2019

Earnings vs. Estimates